Source: FDA, National Drug Code (US) Revision Year: 2026
Veligrotug-vvze, an insulin-like growth factor-1 receptor inhibitor (IGF-1R), is a humanized IgG1κ monoclonal antibody produced in Chinese hamster ovary (CHO-K1) cells. It has a molecular weight of approximately 150 kilodaltons.
LUMVOA (veligrotug-vvze) injection is supplied as a sterile, preservative-free, yellowish to brown, slightly opalescent solution, and free of visible particles, for intravenous infusion. Each single-dose vial contains 500 mg of veligrotug-vvze, histidine (6.50 mg), L-histidine hydrochloride monohydrate (33.1 mg), methionine (14.9 mg), polysorbate 80 (2.0 mg), sucrose (800 mg), and Water for Injection (quantity sufficient to 10 mL). The final concentration is 50 mg/mL with a pH of 5.5.
| Dosage Forms and Strengths |
|---|
|
Injection: 500 mg/10 mL (50 mg/mL) yellowish to brown, slightly opalescent solution in a single-dose vial. |
| How Supplied | ||
|---|---|---|
|
LUMVOA (veligrotug-vvze) injection is a sterile, preservative-free, yellowish to brown, slightly opalescent solution available as follows:
Manufactured by: Viridian Therapeutics, Inc., 221 Crescent Street, Suite 103A, Waltham, MA 02453, U.S. License No. 2377 |
| Drug | Countries | |
|---|---|---|
| LUMVOA | United States |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.